SITE001-0216

SITE001 (USA) › SITE001-0216

SITE001-0216

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE001 (USA) · Dr. Reyes
consented 2026-05-13

enrolled

AEs

5

Serious

1

Dropout signal

–

Adverse events

5

Grade 1 Pneumonitis — outcome: RECOVERED/RESOLVED; onset 2023-02-17 (study day 91); relationship: not assessed

mild assessed

Grade 3 Rash — outcome: RECOVERED/RESOLVED; onset 2023-02-03 (study day 77); relationship: RELATED; serious criteria: hospitalization

severe serious assessed

Grade 1 Vomiting — outcome: RECOVERED/RESOLVED; onset 2023-01-29 (study day 72); relationship: RELATED

mild assessed

Grade 2 Anaemia — outcome: RECOVERED/RESOLVED; onset 2023-01-08 (study day 51); relationship: NOT RELATED

moderate assessed

Grade 2 Dyspnoea — outcome: RECOVERED/RESOLVED; onset 2022-12-27 (study day 39); relationship: not assessed

moderate assessed

Data queries

0

No data queries. Open queries would appear here for this patient.